Connect with us

Hi, what are you looking for?

Business

Sanofi improves outlook on strength of bestseller Dupixent

French drug maker Sanofi has revised its outlook for 2022 upwards after reporting strong sales growth in the third quarter on Friday.

In the first nine months of the year, revenue reached 32.3 billion euros
In the first nine months of the year, revenue reached 32.3 billion euros - Copyright AFP Thomas SAMSON
In the first nine months of the year, revenue reached 32.3 billion euros - Copyright AFP Thomas SAMSON

French drug maker Sanofi has revised its outlook for 2022 upwards after reporting strong sales growth in the third quarter on Friday.

While Sanofi faced struggles in producing a jab against Covid, its Dupixent drug, which treats conditions including asthma and eczema, has been a huge success.

In Q3, sales of Dupixent exceeded the two billion euros mark for the first time, Sanofi said in a statement.

The pharmaceutical giant was also boosted by nearly two billion euros of sales for its flu vaccines, as many countries prepare for the peak winter flu season.

Sanofi said between July and the end of September, net profit fell 10 percent to two billion euros ($2 billion) due to impairments.

But without exceptional items net profit jumped 32 percent to 3.6 billion euros, higher than expected by analysts.

And in the first nine months of the year, revenue reached 32.3 billion euros — an increase of more than 16 percent.

Sanofi now expects earnings per share (EPS) — a measure of a company’s profitability — of around 16 percent for this year, up from earlier predictions.

AFP
Written By

With 2,400 staff representing 100 different nationalities, AFP covers the world as a leading global news agency. AFP provides fast, comprehensive and verified coverage of the issues affecting our daily lives.

You may also like:

Tech & Science

Like many great ideas, YYC DataCon started as a conversation among friends.

Social Media

Digital titans including Facebook and TikTok formally pledged to ramp up the fight against disinformation in the EU.

Business

The US State Department backtracked on a document saying it would award $400 million for electric armored cars by Tesla.